Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report). The associated price target remains the same with $20.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tyler Van Buren has given his Buy rating due to a combination of factors related to EyePoint Pharmaceuticals’ progress in their clinical trials. The company has shown impressive enrollment rates in their Phase III trials for wet age-related macular degeneration (wAMD), with the LUGANO trial over 90% enrolled and the LUCIA trial over 50% enrolled. This rapid pace of enrollment suggests that EyePoint is on track to complete the trials as planned, potentially giving them a first-to-market advantage in the TKI race for wAMD.
Furthermore, the successful completion of these trials could significantly boost EyePoint’s market position, as the LUGANO trial is expected to be a major value-creating event. The LUGANO trial’s results are anticipated to provide confidence in the subsequent LUCIA trial due to their identical designs, thereby reducing risk. The company’s strategic focus on executing these trials efficiently and their potential to meet the FDA’s safety requirements further supports the positive outlook and Buy rating given by Tyler Van Buren.
Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Moderna. According to TipRanks, Van Buren has an average return of -2.8% and a 41.29% success rate on recommended stocks.